1. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. (4th December 2012) Authors: Popat, Rakesh; Plesner, Torben; Davies, Faith; Cook, Gordon; Cook, Mark; Elliott, Peter; Jacobson, Eric; Gumbleton, Todd; Oakervee, Heather; Cavenagh, Jamie Journal: British journal of haematology Issue: Volume 160:Number 5(2013:Mar.) Page Start: 714 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Issue 12 (December 2016) Authors: Popat, Rakesh; Brown, Sarah R; Flanagan, Louise; Hall, Andrew; Gregory, Walter; Kishore, Bhuvan; Streetly, Matthew; Oakervee, Heather; Yong, Kwee; Cook, Gordon; Low, Eric; Cavenagh, Jamie Journal: Lancet Issue: Volume 3:Issue 12(2016) Page Start: e572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients. (10th January 2022) Authors: Caldwell, Louise; Bapat, Anjaneya; Drumright, Lydia N; Lambourne, Jonathan; Jimenez-England, Fergus G; Aries, James; Eccersley, Lydia; Hallam, Simon; Montoto, Silvia; Oakervee, Heather; Riches, John; Agrawal, Samir G Journal: Clinical infectious diseases Issue: Volume 75:Number 1(2022) Page Start: 178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients. (10th June 2020) Authors: Aries, James A.; Davies, Jeffrey K.; Auer, Rebecca L.; Hallam, Simon L.; Montoto, Silvia; Smith, Matthew; Sevillano, Belen; Foggo, Vanessa; Wrench, Bela; Zegocki, Krzysztof; Agrawal, Samir; Le Dieu, Rifca; Truelove, Edward; Erblich, Thomas; Araf, Shamzah; Okosun, Jessica; Oakervee, Heather; Caven... Journal: British journal of haematology Issue: Volume 190:Number 2(2020) Page Start: e64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Durable graft‐versus‐leukaemia effects without donor lymphocyte infusions – results of a phase II study of sequential T‐replete allogeneic transplantation for high‐risk acute myeloid leukaemia and myelodysplasia. (26th October 2017) Authors: Davies, Jeff K.; Hassan, Sandra; Sarker, Shah‐Jalal; Besley, Caroline; Oakervee, Heather; Smith, Matthew; Taussig, David; Gribben, John G.; Cavenagh, Jamie D. Journal: British journal of haematology Issue: Volume 180:Number 3(2018) Page Start: 346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). (20th August 2018) Authors: Popat, Rakesh; Brown, Sarah R.; Flanagan, Louise; Hall, Andrew; Gregory, Walter; Kishore, Bhuvan; Streetly, Matthew; Oakervee, Heather; Yong, Kwee; Cook, Gordon; Low, Eric; Cavenagh, Jamie Journal: British journal of haematology Issue: Volume 185:Number 3(2019) Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long‐term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non‐myeloablative conditioning without T cell depletion. (29th May 2013) Authors: Davies, Jeff K.; Taussig, David; Oakervee, Heather; Smith, Matthew; Agrawal, Samir; Cavenagh, Jamie D.; Gribben, John G. Journal: British journal of haematology Issue: Volume 162:Number 4(2013:Aug.) Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Optimising cardiovascular care of patients with multiple myeloma. Issue 22 (5th April 2021) Authors: Fontes Oliveira, Marta; Naaktgeboren, Willeke R; Hua, Alina; Ghosh, Arjun K; Oakervee, Heather; Hallam, Simon; Manisty, Charlotte Journal: Heart Issue: Volume 107:Issue 22(2021) Page Start: 1774 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high‐risk myeloma patients – a single centre experience. (13th March 2021) Authors: Jurgensen‐Rauch, Amanda; Gibbs, Suzanne; Farrell, Maresa; Aries, James; Grantham, Marianne; Eccersley, Lydia; Gribben, John; Hallam, Simon; Oakervee, Heather; Cavenagh, Jamie; Davies, Jeff; Sive, Jonathan Journal: British journal of haematology Issue: Volume 193:Number 2(2021) Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗